Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30486887 | 0.83 | MTNR1A (0.38) | MTNR1AKDM4ESMN1; SMN2MAPTHPGD | |
| SCHEMBL21979507 | 0.83 | MTNR1A (0.38) | MTNR1AKDM4ESMN1; SMN2MAPTHPGD | |
| SCHEMBL1149967 | 0.81 | KDM4E (0.50) | DHODHKDM4EGAASMN1; SMN2MAPT | |
| SCHEMBL11559734 | 0.74 | KDM4E (0.56) | KDM4EGAAHSD17B10SMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL11563282 | 0.73 | KDM4E (0.54) | KDM4EGAAHSD17B10SMN1; SMN2MAPT | |
| SCHEMBL25942293 | 0.73 | MTNR1A (0.43) | MTNR1AKDM4ESMN1; SMN2HPGDMTNR1B | |
| SCHEMBL25940696 | 0.72 | SMN1; SMN2 (0.53) | KDM4EGAAHSD17B10SMN1; SMN2MAPT | |
| SCHEMBL21979491 | 0.71 | MTNR1A (0.55) | MTNR1ALMNAKDM4EGAAHSD17B10 | |
| SCHEMBL21979475 | 0.71 | EGFR (0.50) | DHODHLMNAKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL25948787 | 0.70 | MTNR1A (0.43) | MTNR1AKDM4ESMN1; SMN2HPGDMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220033399-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-02-03 | — | — | US | disclosed |
| US-11161845-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200165243-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | MTNR1A 116/4885DHODH 3633/4885LMNA 496/4885 |
| US-20200165243-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, TYR, PAH | MTNR1A 1666/4885DHODH 966/4885LMNA 554/4885 |
| US-11161845-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | POLR1C, TYR, PAH | MTNR1A 1623/4885DHODH 973/4885LMNA 564/4885 |
| US-20220033399-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, TYR, PAH | MTNR1A 1585/4885DHODH 985/4885LMNA 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.